scholarly journals Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia

2019 ◽  
Vol 34 (8) ◽  
pp. 1296-1315 ◽  
Author(s):  
Choon Jin Ooi ◽  
Ida Hilmi ◽  
Rupa Banerjee ◽  
Sai Wei Chuah ◽  
Siew Chien Ng ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Best Practices ◽  
Biologic Agents

scholarly journals Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia

2019 ◽  
Vol 17 (3) ◽  
pp. 285-310 ◽  
Author(s):  
Choon Jin Ooi ◽  
Ida Hilmi ◽  
Rupa Banerjee ◽  
Sai Wei Chuah ◽  
Siew Chien Ng ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Best Practices ◽  
Biologic Agents

scholarly journals Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies

2021 ◽  
Vol 64 (9) ◽  
pp. 605-613
Author(s):  
Hyo Yeop Song ◽  
Geom Seog Seo
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Inflammatory Bowel Diseases ◽  
Biologic Agents ◽  
Janus Kinase ◽  
Interleukin 12 ◽  
New Therapies ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Background: The treatment of inflammatory bowel diseases has evolved with the development of anti-tumor necrosis factor agents. Despite the long-term effectiveness, many patients experience primary non-response, secondary loss of response, or intolerance. Therefore, the development of new drugs that act on different inflammatory pathways has become necessary. This review focuses on biologic agents and new therapies for the treatment of inflammatory bowel diseases.Current Concepts: Vedolizumab, a gut-selective agent that targets α4β7 integrin is effective in both ulcerative colitis and Crohn’s disease. Ustekinumab is a monoclonal antibody that binds to p40 subunit of interleukin-12/interleukin-23. Ustekinumab is available for the treatment of Crohn’s disease and ulcerative colitis. Tofacitinib is the first Janus kinase inhibitor approved for the treatment of ulcerative colitis. The advantage of tofacitinib is an oral prescription medicine and has rapid action.Discussion and Conclusion: Since vedolizumab, ustekinumab and tofacitinib are effective agents for the treatment of inflammatory bowel diseases, positioning of old and new biologic agents and small molecules should be determined. The safety and efficacy of novel and emerging drugs needs to be evaluated in patients with inflammatory bowel disease.

scholarly journals Fecal lactoferrin predicts primary non-response to biologic agents in inflammatory bowel disease

2021 ◽  
Author(s):  
Dario Sorrentino ◽  
Vu Q. Nguyen ◽  
Kim Love
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Bowel Disease ◽  
Clinical Remission ◽  
Biologic Agents ◽  
Fecal Lactoferrin ◽  
Inflammatory Bowel

Introduction: Fecal Lactoferrin (FL) is a timely and accurate marker of inflammation in ulcerative colitis (UC) and Crohn’s disease (CD). Aim of this study was to verify whether FL can predict primary non-response (PNR) to biologic agents during induction. Methods: Retrospective outcome review in 27 patients (13 with CD and 14 with UC) tested for baseline FL and re-tested within a week after the first and second induction doses. Clinical/biochemical outcomes were evaluated at end of induction and at follow up (3-24 months). Results: Compared to baseline, changes of the Harvey-Bradshaw (CD) and Partial Mayo Scoring (UC) indices at end of induction separated responders (18/27 or 67%) from non-responders (9/17 or 33%). In all patients the initial FL value at induction decreased compared to baseline, continuing to decrease after the following dose in clinical responders while bouncing back in the others. Models targeting the two consecutively decreased FL values or the second FL value compared to baseline or the second FL value compared to the first were able to accurately predict response at end of induction. Follow-up assessment confirmed clinical remission in initial responders (with FL values reduced on the average by 94±10% compared to baseline). Conclusions: In CD and UC patients during induction with biologic agents early FL measurements accurately separate clinical responders from those experiencing PNR. The method described here offers several potential advantages over other strategies to assess and manage these patients.

Fr555 HOW MANY PATIENTS AFFECTED BY CROHN'S DISEASE OR ULCERATIVE COLITIS NOT TREATED WITH BIOLOGIC AGENTS COULD BE ELIGIBLE FOR THESE THERAPIES IN ITALY?

2021 ◽  
Vol 160 (6) ◽  
pp. S-361
Author(s):  
Luca Degli Esposti ◽  
Valentina Perrone ◽  
Diego Sangiorgi ◽  
Stefania Saragoni ◽  
Elisa Giacomini ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Biologic Agents

Mannan-binding lectin gene polymorphisms in ulcerative colitis and Crohn's disease

2001 ◽  
Vol 120 (5) ◽  
pp. A459-A459
Author(s):  
A RECTOR ◽  
P LEMEY ◽  
W LAFFUT ◽  
E KEYAERTS ◽  
F STRUYF ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Gene Polymorphisms ◽  
Lectin Gene ◽  
Mannan Binding Lectin ◽  
Binding Lectin

RDW can be a useful additional marker in diagnosing Crohn's disease and ulcerative colitis

2008 ◽  
Vol 46 (05) ◽  
Author(s):  
Z Szepes ◽  
K Farkas ◽  
T Molnar ◽  
F Nagy ◽  
T Nyari ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Additional Marker
Sign in / Sign up

Export Citation Format

Share Document